Across TCGA pan-cancer cohorts, IL2RB mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of IL2RB’s most consistent transcriptional readouts.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where IL2RB mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types IL2RB is over-expressed in tumor, although a few such as LSCC show the opposite, repressed pattern.
CCRCC and LSCC are the cancer types where IL2RB tumor–normal differential expression is most reproducible.